(Q43011873)

12 November 2017

title

Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? (English)

1 reference

metastatic renal cell carcinoma

12 November 2017

1 reference

1 reference

Stephen H Culp

1

1 reference

12 November 2017

Nizar M Tannir

2

1 reference

12 November 2017

E Jason Abel

3

1 reference

12 November 2017

Vitaly Margulis

4

1 reference

12 November 2017

Pheroze Tamboli

5

1 reference

12 November 2017

Surena F Matin

6

1 reference

12 November 2017

Christopher G Wood

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

12 November 2017

1 reference

12 November 2017

volume

116

1 reference

12 November 2017

issue

14

1 reference

12 November 2017

page(s)

3378-3388

1 reference

Rising incidence of renal cell cancer in the United States

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

The natural history of metastatic renal cell carcinoma: a computer analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.25046

1 reference

7 January 2021

Nephrectomy for renal cell carcinoma with metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Effect of renal cell carcinomas on the development of type 1 T-cell responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

VASCULAR ENDOTHELIAL GROWTH FACTOR AS PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25046

7 January 2021

Identifiers

DOI

10.1002/CNCR.25046

1 reference

12 November 2017

1 reference